Clinical Trials Directory

Trials / Completed

CompletedNCT02290210

Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients

A Placebo-controlled, Randomized, Double-blind, Multicenter Phase 2 Study to Assess the Efficacy and Safety of URC102 in Gout Patients

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
64 (actual)
Sponsor
JW Pharmaceutical · Industry
Sex
Male
Age
20 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to assess safety, PK/PD and Urate Lowering Effect of URC102 in gout patients with hyperuricemia

Conditions

Interventions

TypeNameDescription
DRUGURC102 0.25mg
DRUGURC102 0.5mg
DRUGURC102 1.0mg
DRUGURC102 2.0mg
DRUGplacebo

Timeline

Start date
2014-07-24
Primary completion
2014-12-02
Completion
2015-08-31
First posted
2014-11-14
Last updated
2017-03-08

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT02290210. Inclusion in this directory is not an endorsement.

Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients (NCT02290210) · Clinical Trials Directory